Business Context and Reporting Period
Company: Alamar Biosciences, Inc. (ALMR)
Filing Type: Form 10-Q (Unaudited)
Period Ended: March 31, 2026
Business Overview: Alamar is a commercial-stage proteomics company developing the ARGO HT System, a high-throughput precision proteomics instrument, and associated consumables and services. The company operates in a single segment focused on enabling early disease detection through protein biomarker analysis. As of March 31, 2026, the company had an installed base of over 100 instruments.
Key Financial Metrics
| Metric (in thousands, except per share) | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | $26,035 | $13,091 |
| Gross Profit | $14,457 | $6,389 |
| Gross Margin | 55.5% | 48.8% |
| Net Loss | $(21,325) | $(7,659) |
| Net Loss Per Share (Basic & Diluted) | $(1.74) | $(0.68) |
| Cash and Cash Equivalents (End of Period) | $64,586 | $30,002 |
| Convertible Notes Outstanding | $65,094 | $0 |
| Term Debt Outstanding | $9,877 | $9,810 |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 99% year-over-year to $26.0 million. Product revenue grew 133% to $21.3 million, driven by a 78% increase in instrument sales and a 178% surge in consumables revenue due to an expanding installed base.
- Operating Expenses: Total operating expenses rose 79% to $26.8 million. Research and Development (R&D) expenses increased 57% to $13.0 million, and Selling, General, and Administrative (SG&A) expenses increased 108% to $13.8 million, reflecting headcount growth and expanded commercial activities.
- Net Loss Expansion: Net loss widened to $21.3 million from $7.7 million. This was significantly impacted by a non-cash loss on remeasurement of convertible notes of $8.6 million recorded in Q1 2026 due to the fair value adjustment of notes issued in January 2026.
- Liquidity: Cash and cash equivalents increased to $64.6 million, bolstered by $56.5 million in proceeds from convertible notes issued in January 2026.
Guidance, Outlook, and Risks
- Subsequent Event (IPO): On April 20, 2026, the company completed its Initial Public Offering (IPO), selling 12,937,500 shares at $17.00 per share. Gross proceeds were $219.9 million, with net proceeds of $197.8 million. The outstanding convertible notes automatically converted into common stock upon the IPO closing.
- Stock Split: A 1-for-2.418 reverse stock split was effected on April 10, 2026. All share data in the filing has been retroactively adjusted.
- Outlook: Management expects to continue incurring significant operating losses as it invests in R&D, manufacturing expansion, and commercialization. The company anticipates full-year 2026 stock-based compensation charges between $13 million and $15 million.
- Key Risks:
- Profitability: The company has incurred losses since inception and expects to continue doing so; there is no assurance it will achieve profitability.
- Legal Proceedings: Ongoing litigation with Olink Proteomics regarding patent infringement (U.S. Patent No. 7,883,848). While an Inter Partes Review (IPR) found the patent claims not unpatentable, the company intends to appeal, and the district court litigation has been lifted from stay.
- Supply Chain: Dependence on single-source suppliers for critical components and antibodies.
- Regulatory: Future products intended for clinical use (ARGO HT/DX) will require FDA marketing authorization, which is uncertain and costly.
Investor Verification Checklist
- IPO Conversion Terms: Verify the final share count and dilution impact resulting from the automatic conversion of the $56.5 million convertible notes and preferred stock into common stock post-IPO.
- Legal Status: Monitor the status of the appeal regarding the Olink Proteomics patent litigation and the outcome of the district court case.
- Consumable Pull-Through: Assess the sustainability of the 178% growth in consumables revenue relative to the instrument installed base growth.
- Capital Expenditures: Review the impact of the new Fremont, California facility lease (up to $33.9 million in future payments) on future cash flows.
- Government Funding Dependency: Evaluate the risk exposure given that a significant portion of revenue comes from academic institutions reliant on government grants (e.g., NIH).